A Phase IIb, Multicenter, Randomised, Double-Blind, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Balcinrenone in Combination With Dapagliflozin Compared With Dapagliflozin in Patients With Chronic Kidney Disease and Albuminuria
Latest Information Update: 23 May 2025
At a glance
- Drugs Balcinrenone (Primary) ; Dapagliflozin (Primary)
- Indications Proteinuria
- Focus Therapeutic Use
- Acronyms MIRO-CKD
- Sponsors AstraZeneca
Most Recent Events
- 16 May 2025 Status changed from active, no longer recruiting to completed.
- 15 Jan 2025 Planned End Date changed from 13 Jan 2026 to 12 May 2025.
- 15 Jan 2025 Planned primary completion date changed from 13 Jan 2026 to 12 May 2025.